drugset / Trial / NCT00242775

Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg

NCT00242775

Phase 3 Completed 2100 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.

Timeline

Start
2005-05
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Fluticasone Other / unclassified 500 ug Inhaled
Subject Formoterol Other / unclassified 4.5 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled

Indications